3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
Doxorubicin
14
Specimen Handling
12
pembrolizumab
11
Magnetic Resonance Spectroscopy
10
Biopsy
10
Cyclophosphamide
9
X-Rays
7
Radiotherapy
7
Ifosfamide
7
Phantoms, Imaging
6
Nivolumab
6
Gemcitabine
6
tazemetostat
5
liposomal doxorubicin
5
Temozolomide
5
Radiation
5
palbociclib
4
fludarabine
4
Nuclear Medicine Department, Hospital
4
Irinotecan
4
larotrectinib
3
cabozantinib
3
atezolizumab
3
Trabectedin
3
Surveys and Questionnaires
3
Radiation Dose Hypofractionation
3
Proton Therapy
3
Ipilimumab
3
Carboplatin
3
Bevacizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Histamine H2 Antagonists
×
90 days
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled